Nucleocapsid Specific Diagnostics for the Detection of Divergent SARS-CoV-2 Variants

Since the start of the COVID-19 pandemic, multiple waves of SARS-CoV-2 variants have emerged. Of particular concern is the omicron variant, which harbors 28 mutations in the spike glycoprotein receptor binding and N-terminal domains relative to the ancestral strain. The high mutability of SARS-CoV-2...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 13; p. 926262
Main Authors Isaacs, Ariel, Amarilla, Alberto A., Aguado, Julio, Modhiran, Naphak, Albornoz, Eduardo A., Baradar, Alireza A., McMillan, Christopher L. D., Choo, Jovin J. Y., Idris, Adi, Supramaniam, Aroon, McMillan, Nigel A. J., Muller, David A., Young, Paul R., Woodruff, Trent M., Wolvetang, Ernst J., Chappell, Keith J., Watterson, Daniel
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 10.06.2022
Subjects
Online AccessGet full text
ISSN1664-3224
1664-3224
DOI10.3389/fimmu.2022.926262

Cover

More Information
Summary:Since the start of the COVID-19 pandemic, multiple waves of SARS-CoV-2 variants have emerged. Of particular concern is the omicron variant, which harbors 28 mutations in the spike glycoprotein receptor binding and N-terminal domains relative to the ancestral strain. The high mutability of SARS-CoV-2 therefore poses significant hurdles for development of universal assays that rely on spike-specific immune detection. To address this, more conserved viral antigens need to be targeted. In this work, we comprehensively demonstrate the use of nucleocapsid (N)-specific detection across several assays using previously described nanobodies C2 and E2. We show that these nanobodies are highly sensitive and can detect divergent SARS-CoV-2 ancestral, delta and omicron variants across several assays. By comparison, spike-specific antibodies S309 and CR3022 only disparately detect SARS-CoV-2 variant targets. As such, we conclude that N-specific detection could provide a standardized universal target for detection of current and emerging SARS-CoV-2 variants of concern.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by: Hinh Ly, University of Minnesota Twin Cities, United States
Reviewed by: Mythili Dileepan, University of Minnesota Twin Cities, United States; Junjie Shao, Pharmgate Biologics, United States
These authors have contributed equally to this work and share first authorship
This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2022.926262